RT Journal Article
SR Electronic
T1 SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.07.22277128
DO 10.1101/2022.07.07.22277128
A1 Aggarwal, Anupriya
A1 Akerman, Anouschka
A1 Milogiannakis, Vanessa
A1 Silva, Mariana Ruiz
A1 Walker, Gregory
A1 Kidinger, Andrea
A1 Angelovich, Thomas
A1 Waring, Emily
A1 Amatayakul-Chantler, Supavadee
A1 Roth, Nathan
A1 Coppola, Germano
A1 Yeang, Malinna
A1 Jean, Tyra
A1 Foster, Charles
A1 Hoppe, Alexandra Carey
A1 Ling Munier, C. Mee
A1 Darley, David
A1 Churchill, Melissa
A1 Starck, Damian
A1 Christ, Daniel
A1 Matthews, Gail
A1 Rawlinson, William
A1 Kelleher, Anthony D.
A1 Turville, Stuart
YR 2022
UL http://medrxiv.org/content/early/2022/07/10/2022.07.07.22277128.abstract
AB Genetically distinct viral variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been recorded since January 2020. Over this time global vaccine programs have been introduced, contributing to lower COVID-19 hospitalisation and mortality rates, particularly in developed countries. In late 2021, the Omicron BA.1 variant emerged, with substantially different genetic differences and clinical effects from other variants of concern (VOC). This variant demonstrated higher numbers of polymorphisms in the gene encoding the Spike (S) protein, and it has displaced the previously dominant Delta variant. Shortly after dominating global spread in early 2022, BA.1 was supplanted by the genetically distinct Omicron lineage BA.2. A sub-lineage of BA.2, designated BA.5 has now started to dominate globally, with the potential to supplant BA.2. To address the relative threat of BA.5, we determined infectivity to particle ratios in primary nasopharyngeal samples and expanded low passage isolates in a well characterised, genetically engineered ACE2/TMPRSS2 cell line. We then assessed the impact of BA.5 infection on humoral neutralisation in vitro, in vaccinated and convalescent cohorts, using concentrated human IgG pooled from thousands of plasma donors, and licensed monoclonal antibody therapies. The infectivity of virus in primary swabs and expanded isolates revealed that whilst BA.1 and BA.2 are attenuated through ACE2/TMPRSS2, BA.5 infectivity is equivalent to that of an early 2020 circulating clade and has greater sensitivity to the TMPRSS2 inhibitor Nafamostat. As with BA.1, we observed BA.5 to significantly reduce neutralisation titres across all donors. Concentrated pooled human IgG from convalescent and vaccinated donors had greater breadth of neutralisation, although the potency was still reduced 7-fold with BA.5. Of all therapeutic antibodies tested, we observed a 14.3-fold reduction using Evusheld and 16.8-fold reduction using Sotrovimab when neutralising a Clade A versus BA.5 isolate. These results have implications for ongoing tracking and management of Omicron waves globally.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMRF2005760/Department of Health | National Health and Medical Research Council (NHMRC) MRF2001684/Department of Health | National Health and Medical Research Council (NHMRC) Covid Rd 2 Grant/NSW Ministry of Health (NSW Health)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All human serum samples were obtained with written informed consent from the participants (2020/ETH00964; 2020/ETH02068) and are approved through the St Vincents Hospital Sydney NSW Ethics committeeI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. Upon publication we will provide data through Figshare